Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study

@article{Angioli2013FeasibilityAS,
  title={Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study},
  author={Roberto Angioli and Francesco Plotti and Daniela Luvero and Alessia Aloisi and Federica Guzzo and Stella Capriglione and Corrado Terranova and Carlo Nardone and Pierluigi Benedetti-Panici},
  journal={Tumor Biology},
  year={2013},
  volume={35},
  pages={2741-2746}
}
The aim of this study is to evaluate the efficacy and safety of the combination of carboplatin and paclitaxel as neoadjuvant chemotherapy (NACT) in patients affected by locally advanced cervical cancer. Between June 2007 and May 2012, all patients with a diagnosis of locally advanced cervical cancer (IB2–IIB) were eligible for this protocol. All patients have received 3 cycles of carboplatin (AUC6) and paclitaxel 175 mg/mq in neoadjuvant setting. The NACT-induced toxicity and the response to… CONTINUE READING